• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy.

作者信息

Halsey Brenton, Fish Elizabeth McAuley, Lyons Walker, McShane Melissa, Williams Austin D

机构信息

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

出版信息

Gland Surg. 2025 Jul 31;14(7):1183-1186. doi: 10.21037/gs-2025-178. Epub 2025 Jul 28.

DOI:10.21037/gs-2025-178
PMID:40771385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12322772/
Abstract
摘要

相似文献

1
Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy.对于淋巴结疾病有限的乳腺癌患者，不应进行腋窝清扫以确定阿贝西利的适用性。
Gland Surg. 2025 Jul 31;14(7):1183-1186. doi: 10.21037/gs-2025-178. Epub 2025 Jul 28.
2
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.完成腋窝淋巴结清扫术以确定 pN2-3 状态作为辅助 CDK4/6 抑制剂治疗的指征：随机、III 期 SENOMAC 试验的事后分析。
Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.
3
Should abemaciclib candidacy be an indication for ALND?-commentary on SENOMAC post-hoc analysis.阿贝西利的适用情况是否应作为腋窝淋巴结清扫术的指征？——关于SENOMAC事后分析的评论
Gland Surg. 2025 Apr 30;14(4):776-780. doi: 10.21037/gs-2025-38. Epub 2025 Apr 25.
4
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.HR+/HER2-早期乳腺癌的真实世界NATALEE和monarchE合格人群特征：美国电子健康记录数据库分析
ESMO Open. 2025 Jun;10(6):105304. doi: 10.1016/j.esmoop.2025.105304. Epub 2025 Jun 13.
5
Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.符合辅助性CDK4/6抑制剂治疗条件的乳腺癌患者的真实世界分析。
Clin Breast Cancer. 2025 Feb;25(2):e159-e169.e2. doi: 10.1016/j.clbc.2024.08.022. Epub 2024 Aug 29.
6
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.绝经后 HR 阳性/HER2 阴性乳腺癌患者接受来曲唑一线治疗，当前辅助内分泌治疗试验 NATALEE 和 monarchE 的选择标准对预后的影响。
Eur J Cancer. 2024 Sep;209:114239. doi: 10.1016/j.ejca.2024.114239. Epub 2024 Jul 21.
7
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.阿贝西利联合氟维司群用于 CDK4/6 抑制剂治疗后进展的晚期乳腺癌：III 期 postMONARCH 试验结果
J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
8
Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?对于激素受体阳性、HER2 阴性乳腺癌且有一个或两个前哨淋巴结阳性的患者，是否应行腋窝清扫术以确定辅助阿贝西利治疗的适应证？
Cancer. 2024 Apr 1;130(7):1052-1060. doi: 10.1002/cncr.35136. Epub 2023 Nov 29.
9
Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.临床医生指南：早期乳腺癌患者使用CDK4/6抑制剂的专家见解
Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.
10
Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.阿贝西利在原发性乳腺癌中的作用：MonarchE研究的叙述性综述
Transl Breast Cancer Res. 2022 Jan 31;3:3. doi: 10.21037/tbcr-21-27. eCollection 2022.

本文引用的文献

1
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor.为何我们不建议乳腺癌女性接受CDK4/6抑制剂辅助治疗。
J Clin Oncol. 2025 Aug;43(22):2456-2460. doi: 10.1200/JCO-24-02683. Epub 2025 Apr 14.
2
Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances-Time to Pause and Reflect?使用MonarchE标准的阿贝西利治疗导致大量额外的腋窝淋巴结清扫——是时候暂停并反思了？
Cancers (Basel). 2024 Sep 4;16(17):3072. doi: 10.3390/cancers16173072.
3
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
完成腋窝淋巴结清扫术以确定 pN2-3 状态作为辅助 CDK4/6 抑制剂治疗的指征：随机、III 期 SENOMAC 试验的事后分析。
Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.
4
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.省略腋窝清扫术治疗前哨淋巴结转移乳腺癌。
N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
5
Quality of Life After Axillary Lymph Node Dissection Among Racial and Ethnic Minority Women.少数民族裔女性腋窝淋巴结清扫术后的生活质量。
JAMA Surg. 2024 Jun 1;159(6):668-676. doi: 10.1001/jamasurg.2024.0118.
6
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
7
Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.重新思考手术修正：MonarchE 试验对激素阳性 HER2 阴性早期乳腺癌患者腋窝清扫术的影响，这些患者有资格接受 abemaciclib 治疗。
Br J Cancer. 2024 Apr;130(7):1141-1148. doi: 10.1038/s41416-024-02580-3. Epub 2024 Jan 27.
8
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.辅助阿贝西利联合内分泌治疗激素受体阳性、人表皮生长因子受体 2 阴性、高危早期乳腺癌： monarchE 总生存期中期分析的预先计划结果，包括 5 年疗效结果。
J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9.
9
Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?对于激素受体阳性、HER2 阴性乳腺癌且有一个或两个前哨淋巴结阳性的患者，是否应行腋窝清扫术以确定辅助阿贝西利治疗的适应证？
Cancer. 2024 Apr 1;130(7):1052-1060. doi: 10.1002/cncr.35136. Epub 2023 Nov 29.
10
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.